Click Therapeutics

News

UK partnership aims to support NHS use of depression app

Otsuka has teamed up with one of the innovation arms of the NHS to explore how a digital therapeutic (DTx) for major depressive disorder (MDD) could be deployed within the health service.

News

Click buys Better assets to speed its digital obesity drive

Click Therapeutics has snapped up the assets of troubled digital health company Better Therapeutics, including its FDA-approved prescription digital therapeutic (PDT) for

News

FDA clears first DTx for depression from Otsuka, Click

Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder.

News

Click bags FDA breakthrough tag for schizophrenia DTx

Digital health company Click Therapeutics has won an FDA breakthrough device designation for CT-155, a digital therapeutic (DTx) for the negative symptoms of schizophrenia

News

Can Pear bud again? Ex-CEO McCann bids for assets

Digital therapeutics (DTx) company Pear Therapeutics may be heading for a new lease of life, if a plan by former chief executive Corey McCann pays off.

News